An oral vaccine based on U-Omp19 induces protection against B. abortus mucosal challenge by inducing an adaptive IL-17 immune response in mice

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Pasquevich, Karina A ^a,b   Ibañez, Andrés E ^a,b   Coria, Lorena M ^a,b   Samartino, Clara García ^a,b   Estein, Silvia M ^c   Zwerdling, Astrid ^a,b   Barrionuevo, Paula ^a,b   Oliveira, Fernanda S ^d   Seither, Christine ^e   Warzecha, Heribert ^e   Oliveira, Sergio C ^d   Giambartolomei, Guillermo H ^a,b   Cassataro, Juliana ^a,b  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c UNIVERSIDAD NACIONAL DEL CENTRO DE LA PROVINCIA DE BUENOS AIRES   (Argentina)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^e DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRUCELLA VACCINE; INTERLEUKIN 17; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN U OMP19; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; LIPOPROTEIN; OMP19 PROTEIN, BRUCELLA ABORTUS;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BRUCELLA ABORTUS; BRUCELLOSIS; CD4+ T LYMPHOCYTE; CELL PROTECTION; CELLULAR IMMUNITY; COLONY FORMING UNIT; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; IMMUNITY; IMMUNIZATION; MOUSE; NONHUMAN; PLANT LEAF; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; TRANSGENE; ANIMAL; IMMUNOLOGY; TH1 CELL; TH17 CELL;

BACTERIA (MICROORGANISMS); BRUCELLA; BRUCELLA MELITENSIS BIOVAR ABORTUS; MUS;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BRUCELLA ABORTUS; BRUCELLA VACCINE; BRUCELLOSIS; CD4-POSITIVE T-LYMPHOCYTES; INTERLEUKIN-17; LIPOPROTEINS; MICE; TH1 CELLS; TH17 CELLS;

EID: 79251592270     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016203     Document Type: Article

References (66)

1. Neutra MR, Kozlowski PA (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6: 148-158.
2. Sala F, Manuela Rigano M, Barbante A, Basso B, Walmsley AM, et al. (2003) Vaccine antigen production in transgenic plants: strategies, gene constructs and perspectives. Vaccine 21: 803-808.
3. Shewen PE, Carrasco-Medina L, McBey BA, Hodgins DC (2009) Challenges in mucosal vaccination of cattle. Vet Immunol Immunopathol 128: 192-198.
4. Gorvel JP (2008) Brucella: a Mr "Hide" converted into Dr Jekyll. Microbes Infect 10: 1010-1013.
5. Kohler S, Michaux-Charachon S, Porte F, Ramuz M, Liautard JP (2003) What is the nature of the replicative niche of a stealthy bug named Brucella? Trends Microbiol 11: 215-219.
6. Golding B, Scott DE, Scharf O, Huang LY, Zaitseva M, et al. (2001) Immunity and protection against Brucella abortus. Microbes Infect 3: 43-48.
7. Roth F, Zinsstag J, Orkhon D, Chimed-Ochir G, Hutton G, et al. (2003) Human health benefits from livestock vaccination for brucellosis: case study. Bull World Health Organ 81: 867-876.
8. Nicoletti P (1990) Vaccination against Brucella. Adv Biotechnol Processes 13: 147-168.
9. Schurig GG, Sriranganathan N, Corbel MJ (2002) Brucellosis vaccines: past, present and future. Vet Microbiol 90: 479-496.
10. Ashford DA, di Pietra J, Lingappa J, Woods C, Noll H, et al. (2004) Adverse events in humans associated with accidental exposure to the livestock brucellosis vaccine RB51. Vaccine 22: 3435-3439.
11. Cassataro J, Estein SM, Pasquevich KA, Velikovsky CA, de la Barrera S, et al. (2005) Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection. Infect Immun 73: 8079-8088.
12. Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Velikovsky CA, et al. (2007) A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. Vaccine 25: 4437-4446.
13. Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Zwerdling A, et al. (2007) A DNA vaccine coding for the chimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination. Vaccine 25: 5958-5967.
14. Cassataro J, Velikovsky CA, Bruno L, Estein SM, de la Barrera S, et al. (2007) Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding Brucella melitensis outer membrane protein 31 (Omp31) and recombinant Omp31 boosting. Clin Vaccine Immunol 14: 869-874.
15. Cassataro J, Velikovsky CA, de la Barrera S, Estein SM, Bruno L, et al. (2005) A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response. Infect Immun 73: 6537-6546.
16. Pasquevich KA, Estein SM, Garcia Samartino C, Zwerdling A, Coria LM, et al. (2009) Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection. Infect Immun 77: 436-445.
17. Magnani DM, Harms JS, Durward MA, Splitter GA (2009) Nondividing but metabolically active gamma-irradiated Brucella melitensis is protective against virulent B. melitensis challenge in mice. Infect Immun 77: 5181-5189.
18. Cabrera A, Saez D, Cespedes S, Andrews E, Onate A (2009) Vaccination with recombinant Semliki Forest virus particles expressing translation initiation factor 3 of Brucella abortus induces protective immunity in BALB/c mice. Immunobiology 214: 467-474.
19. Baldwin CL, Parent M (2002) Fundamentals of host immune response against Brucella abortus: what the mouse model has revealed about control of infection. Vet Microbiol 90: 367-382.
20. Perkins SD, Smither SJ, Atkins HS (2010) Towards a Brucella vaccine for humans. FEMS Microbiol Rev.
21. Happel KI, Dubin PJ, Zheng M, Ghilardi N, Lockhart C, et al. (2005) Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J Exp Med 202: 761-769.
22. Ye P, Garvey PB, Zhang P, Nelson S, Bagby G, et al. (2001) Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol 25: 335-340.
23. Umemura M, Yahagi A, Hamada S, Begum MD, Watanabe H, et al. (2007) IL- 17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J Immunol 178: 3786-3796.
24. Huang W, Na L, Fidel PL, Schwarzenberger P (2004) Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 190: 624-631.
25. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, et al. (2007) IL- 23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8: 369-377.
26. Tibor A, Decelle B, Letesson JJ (1999) Outer membrane proteins Omp10, Omp16, and Omp19 of Brucella spp. are lipoproteins. Infect Immun 67: 4960-4962.
27. Fiorentino MA, Campos E, Cravero S, Arese A, Paolicchi F, et al. (2008) Protection levels in vaccinated heifers with experimental vaccines Brucella abortus M1-luc and INTA 2. Vet Microbiol 132: 302-311.
28. Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11: S45-53.
29. Fujihashi K, Koga T, van Ginkel FW, Hagiwara Y, McGhee JR (2002) A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxinbased adjuvants. Vaccine 20: 2431-2438.
30. Mason HS, Warzecha H, Mor T, Arntzen CJ (2002) Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine. Trends Mol Med 8: 324-329.
31. Streatfield SJ (2006) Mucosal immunization using recombinant plant-based oral vaccines. Methods 38: 150-157.
32. Marillonnet S, Giritch A, Gils M, Kandzia R, Klimyuk V, et al. (2004) In planta engineering of viral RNA replicons: efficient assembly by recombination of DNA modules delivered by Agrobacterium. Proc Natl Acad Sci U S A 101: 6852-6857.
33. Pasquali P, Rosanna A, Pistoia C, Petrucci P, Ciuchini F (2003) Brucella abortus RB51 induces protection in mice orally infected with the virulent strain B. abortus 2308. Infect Immun 71: 2326-2330.
34. Brown LE, Jackson DC (2005) Lipid-based self-adjuvanting vaccines. Curr Drug Deliv 2: 383-393.
35. Giambartolomei GH, Zwerdling A, Cassataro J, Bruno L, Fossati CA, et al. (2004) Lipoproteins, not lipopolysaccharide, are the key mediators of the proinflammatory response elicited by heat-killed Brucella abortus. J Immunol 173:4635-4642.
36. Murphy EA, Sathiyaseelan J, Parent MA, Zou B, Baldwin CL (2001) Interferongamma is crucial for surviving a Brucella abortus infection in both resistant C57BL/6 and susceptible BALB/c mice. Immunology 103: 511-518.
37. Bowden RA, Estein SM, Zygmunt MS, Dubray G, Cloeckaert A (2000) Identification of protective outer membrane antigens of Brucella ovis by passive immunization of mice with monoclonal antibodies. Microbes Infect 2: 481-488.
38. Pashine A, Valiante NM, Ulmer JB (2005) Targeting the innate immune response with improved vaccine adjuvants. Nat Med 11: S63-68.
39. Reed SG, Bertholet S, Coler RN, Friede M (2009) New horizons in adjuvants for vaccine development. Trends Immunol 30: 23-32.
40. Liljeqvist S, Stahl S (1999) Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. J Biotechnol 73: 1-33.
41. Stevens MG, Olsen SC, Pugh GW, Jr., Brees D (1995) Comparison of immune responses and resistance to brucellosis in mice vaccinated with Brucella abortus 19 or RB51. Infect Immun 63: 264-270.
42. Izadjoo MJ, Bhattacharjee AK, Paranavitana CM, Hadfield TL, Hoover DL (2004) Oral vaccination with Brucella melitensis WR201 protects mice against intranasal challenge with virulent Brucella melitensis 16M. Infect Immun 72: 4031-4039.
43. Stabel TJ, Mayfield JE, Tabatabai LB, Wannemuehler MJ (1990) Oral immunization of mice with attenuated Salmonella typhimurium containing a recombinant plasmid which codes for production of a 31-kilodalton protein of Brucella abortus. Infect Immun 58: 2048-2055.
44. Pontes DS, Dorella FA, Ribeiro LA, Miyoshi A, Le Loir Y, et al. (2003) Induction of partial protection in mice after oral administration of Lactococcus lactis producing Brucella abortus L7/L12 antigen. J Drug Target 11: 489-493.
45. Al-Mariri A, Tibor A, Lestrate P, Mertens P, De Bolle X, et al. (2002) Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen. Infect Immun 70: 1915-1923.
46. Delpino MV, Marchesini MI, Estein SM, Comerci DJ, Cassataro J, et al. (2007) A bile salt hydrolase of Brucella abortus contributes to the establishment of a successful infection through the oral route in mice. Infect Immun 75: 299-305.
47. Pasquevich KA, Garcia Samartino C, Coria LM, Estein SM, Zwerdling A, et al. The protein moiety of Brucella abortus outer membrane protein 16 is a new bacterial pathogen-associated molecular pattern that activates dendritic cells in vivo, induces a Th1 immune response, and is a promising self-adjuvanting vaccine against systemic and oral acquired brucellosis. J Immunol 184: 5200-5212.
48. Rice J, Ainley WM, Shewen P (2005) Plant-made vaccines: biotechnology and immunology in animal health. Anim Health Res Rev 6: 199-209.
49. Freytag LC, Clements JD (2005) Mucosal adjuvants. Vaccine 23: 1804-1813.
50. Baldwin CL, Goenka R (2006) Host immune responses to the intracellular bacteria Brucella: does the bacteria instruct the host to facilitate chronic infection? Crit Rev Immunol 26: 407-442.
51. Khader SA, Gaffen SL, Kolls JK (2009) Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol 2: 403-411.
52. Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27: 485-517.
53. Matsuzaki G, Umemura M (2007) Interleukin-17 as an effector molecule of innate and acquired immunity against infections. Microbiol Immunol 51: 1139-1147.
54. Curtis MM, Way SS (2009) Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology 126: 177-185.
55. Lin Y, Ritchea S, Logar A, Slight S, Messmer M, et al. (2009) Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 31: 799-810.
56. Meeks KD, Sieve AN, Kolls JK, Ghilardi N, Berg RE (2009) IL-23 is required for protection against systemic infection with Listeria monocytogenes. J Immunol 183: 8026-8034.
57. Sieve AN, Meeks KD, Bodhankar S, Lee S, Kolls JK, et al. (2009) A novel IL- 17 dependent mechanism of cross protection: respiratory infection with mycoplasma protects against a secondary listeria infection. Eur J Immunol 39: 426-438.
58. Khader SA, Cooper AM (2008) IL-23 and IL-17 in tuberculosis. Cytokine 41: 79-83.
59. Schulz SM, Kohler G, Holscher C, Iwakura Y, Alber G (2008) IL-17A is produced by Th17, gammadelta T cells and other CD4- lymphocytes during infection with Salmonella enterica serovar Enteritidis and has a mild effect in bacterial clearance. Int Immunol 20: 1129-1138.
60. Schulz SM, Kohler G, Schutze N, Knauer J, Straubinger RK, et al. (2008) Protective immunity to systemic infection with attenuated Salmonella enterica serovar enteritidis in the absence of IL-12 is associated with IL-23-dependent IL- 22, but not IL-17. J Immunol 181: 7891-7901.
61. Raffatellu M, Santos RL, Verhoeven DE, George MD, Wilson RP, et al. (2008) Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med 14: 421-428.
62. Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, et al. (2009) Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 5: e1000703.
63. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH (2006) TLR4 mediates vaccineinduced protective cellular immunity to Bordetella pertussis: role of IL-17- producing T cells. J Immunol 177: 7980-7989.
64. Priebe GP, Walsh RL, Cederroth TA, Kamei A, Coutinho-Sledge YS, et al. (2008) IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. J Immunol 181: 4965-4975.
65. Velikovsky CA, Goldbaum FA, Cassataro J, Estein S, Bowden RA, et al. (2003) Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used. Infect Immun 71: 5750-5755.
66. Jimenez de Bagues MP, Elzer PH, Blasco JM, Marin CM, Gamazo C, et al. (1994) Protective immunity to Brucella ovis in BALB/c mice following recovery from primary infection or immunization with subcellular vaccines. Infect Immun 62: 632-638.